<DOC>
	<DOCNO>NCT01216020</DOCNO>
	<brief_summary>BACKGROUND : Concomitant radiotherapy cisplatin ( CDDP ) base chemotherapy standard treatment LA-NHSCC . This combined modality treatment link considerable acute local systemic toxicity.EGFR overexpressed 90-100 % HNSCC case consider unfavourable prognostic marker . EGFR costitutive activation link HNSCC pathogenesis . Cetuximab monoclonal anti-EGFR antibody block activation receptor signal transduction . Cetuximab combine radiotherapy superior radiotherapy treatment LA-HNSCC characterize acceptable toxicity profile . RATIONALE : A direct comparison concomitant chemoradiotherapy Cisplatin concomitant treatment radiotherapy associate cetuximab exist . STUDY DESIGN : Arm A : Radical radiotherapy ( dose volume ) concomitant chemotherapy Cisplatin ( 40 mg/mq/week ) Arm B : Radical radiotherapy ( dose volume ) concomitant therapy monoclonal antibody Cetuximab ( 400 mg/m2 [ `` load dose '' ] subsequently 250 mg /m2/week )</brief_summary>
	<brief_title>Cetuximab Plus Radiotherapy Versus Cisplatin Plus Radiotherapy Locally Advanced Head Neck Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : Evaluation comparison compliance two treatment ; SECONDARY OBJECTIVES : Evaluation comparison grade incidence acute toxicity ; Evaluation comparison local control ; Evaluation comparison event free survival ( local control distant metastasis ) ; Evaluation comparison cause specific overall survival . INCLUSION/EXCLUSION CRITERIA - Histologically confirm squamous cell carcinoma ( biopsy obtain tumor and/or lymphnodal metastasis ) originate oral cavity , oropharynx , hypopharinx , supraglottic larynx ; - Locally advanced disease , define one follow criterion : every T , N+ , M0 ( T1 , N1 case exclude ) ; T3-4 , N0 , M0 ; - Not nasopharynx , paranasal sinus , salivary gland tumor ; - General condition concomitant disease consider contraindication chemotherapy curative radiotherapy ; - No surgical , chemotherapeutic radiotherapic treatment ENT region tumor tumor anatomical site ( exception non-melanoma cutaneous tumor carcinoma situ uterine cervix solid tumor whose primary treatment complete 3 year accrual study never relapse since primary treatment ( patient since continuously disease- free ) ; - Availability follow-up ; - Signed informed consent ; - An interval maximum 3 week stag procedure local disease randomization - An interval maximum 2 week randomization onset treatment</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<mesh_term>Mouth Neoplasms</mesh_term>
	<mesh_term>Pharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically confirm squamous cell carcinoma ( biopsy primary / lymph node metastasis ) oral cavity , oropharynx , hypopharynx , larynx supraglottix ; Locally advance disease , define one follow criterion : T , N + , M0 ( exclude T1 , N1 ) , T34 , N0 , M0 ; Not cancer nasopharynx paranasal sinuses salivary gland ; General condition associate disease allow perform chemotherapy radiotherapy radical view ; No surgical treatment , chemotherapy radiotherapy cancer head neck elsewhere , except nonmelanoma skin cancer situ cervical cancer solid tumor radical treatment complete &gt; three year prior enrollment study patient remain continuously free disease ; Accessibility followup ; Signing inform consent ; Interval examination local stag randomization , maximum 3 week Interval randomization initiation treatment , maximum 2 week Age &lt; 18 year ECOG performance status &gt; 01 Hemoglobin &lt; 9 g / dL Counts granulocytes , total &lt; 1.5 x 10 ^ 9 / L Platelet count &lt; 100 x 10 ^ 9 / L Bilirubin &gt; 1.5 time upper limit normal ( ULN ) AST ALT &gt; 3 time ULN Creatinine clearance &gt; 50 mL/min Mg &gt; 0.5 mmol/L Pregnancy lactation Presence allergy study drug excipients use formulation Peripheral neuropathy ≥ grade 2 ( CTCAE v3.0 ) Hearing loss / tinnitus ≥ grade 3 ( CTCAE v3.0 ) One follow condition : Myocardial infarction within 12 month prior randomization Severe congestive heart failure Unstable angina Cardiomyopathy act Ventricular arrhythmia uncontrolled hypertension Severe psychotic disorder act Severe infection act Any serious illness could interfere administration therapy provide protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Cisplatin</keyword>
</DOC>